晚期非小细胞肺癌靶向治疗的研究进展(3)
[7]Lindeman NI，Cagle PT，Beasley MB，et al.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors：guideline from the College of American Pathologists，International Association for the Study of Lung Cancer，and Association for Molecular Pathology[J].J Mol Diagn，2013，15(4)：415-453.
[8]Mok T，Kim DW，Wu YL，et al.First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients with advanced ALK-positive non-squamous non small cell lung cancer：results of a phase III study(PROFILE 1014)[J].N Engl J Med，2014，371：2167-2177.
, http://www.100md.com
[9]Shaw AT，Kim DW，Mehra R，et al.Ceritinib in ALK-rearranged non small cell lung cancer[J].N Engl J Med，2014，370(13)：1189-1197.
[10]Shaw AT，Ou SH，Bang YJ，et al.Crizotinib in ROS1-rearranged non small cell lung cancer[J].N Engl J Med，2014，371(21)：1963-1971.
[11]Tissot C，Couraud S，Tanguy R，et al.Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations[J].Lung Cancer，2016，91：23-28.
, 百拇医药
[12]Planchard D，Mazieres J，Riely G J，et al.Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients[J].Annuaire Fran？ais De Droit International，2013，44(1)：114-143.
[13]Janne PA，Shaw AT，Pereira JR，et al.Selumetinib plus docetaxel for KRAS-mutant advanced non small cell lung cancer：a randomised，multicentre，placebo-controlled，phase 2 study[J].Lancet Oncol，2013，14(1)：38-47.
, http://www.100md.com
[14]Chi F，Wu R，Jin X，et al.HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway[J].Onco Targets Ther，2016，5(9)：2709-2716.
[15]Drilon A，Wang L，Hasanovic A，et al.Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas[J].Cancer Discov，2013，3(6)：630-635.
[16]Vaishnavi A，Capelletti M，Le AT，et al.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer[J].Nat Med，2013，19(11)：1469-1472.
, 百拇医药
[17]Nogova L，Sequist LV，Cassier PA，et al.Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398[J].J Clin Oncol，2014，7：237-241.
[18]Miao L，Wang Y，Zhu S，et al.Identication of novel driver mutations of the discoidin domain receptor 2(DDR2)gene in squamous cell lung cancer of Chinese patients[J].BMC Cancer，2014，14：369-379.
[19]Pitini V，Arrigo C，Di Mirto C，et al.Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia[J].Lung Cancer，2013，82(1)：171-172.編辑/王朵梅, http://www.100md.com(郁云龙 温冰)
[8]Mok T，Kim DW，Wu YL，et al.First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients with advanced ALK-positive non-squamous non small cell lung cancer：results of a phase III study(PROFILE 1014)[J].N Engl J Med，2014，371：2167-2177.
, http://www.100md.com
[9]Shaw AT，Kim DW，Mehra R，et al.Ceritinib in ALK-rearranged non small cell lung cancer[J].N Engl J Med，2014，370(13)：1189-1197.
[10]Shaw AT，Ou SH，Bang YJ，et al.Crizotinib in ROS1-rearranged non small cell lung cancer[J].N Engl J Med，2014，371(21)：1963-1971.
[11]Tissot C，Couraud S，Tanguy R，et al.Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations[J].Lung Cancer，2016，91：23-28.
, 百拇医药
[12]Planchard D，Mazieres J，Riely G J，et al.Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients[J].Annuaire Fran？ais De Droit International，2013，44(1)：114-143.
[13]Janne PA，Shaw AT，Pereira JR，et al.Selumetinib plus docetaxel for KRAS-mutant advanced non small cell lung cancer：a randomised，multicentre，placebo-controlled，phase 2 study[J].Lancet Oncol，2013，14(1)：38-47.
, http://www.100md.com
[14]Chi F，Wu R，Jin X，et al.HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway[J].Onco Targets Ther，2016，5(9)：2709-2716.
[15]Drilon A，Wang L，Hasanovic A，et al.Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas[J].Cancer Discov，2013，3(6)：630-635.
[16]Vaishnavi A，Capelletti M，Le AT，et al.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer[J].Nat Med，2013，19(11)：1469-1472.
, 百拇医药
[17]Nogova L，Sequist LV，Cassier PA，et al.Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398[J].J Clin Oncol，2014，7：237-241.
[18]Miao L，Wang Y，Zhu S，et al.Identication of novel driver mutations of the discoidin domain receptor 2(DDR2)gene in squamous cell lung cancer of Chinese patients[J].BMC Cancer，2014，14：369-379.
[19]Pitini V，Arrigo C，Di Mirto C，et al.Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia[J].Lung Cancer，2013，82(1)：171-172.編辑/王朵梅, http://www.100md.com(郁云龙 温冰)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺肿瘤 > 肺癌